“Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 1, Jan. 2021, p. s2, https://doi.org/10.25251/skin.5.supp.2.